We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+34.33%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.26B
AUM Growth
+$251M
Cap. Flow
-$193M
Cap. Flow %
-4.53%
Top 10 Hldgs %
40.49%
Holding
127
New
24
Increased
16
Reduced
24
Closed
18

Top Buys

Rank Stock Value
1
DHR icon
Danaher
DHR
+$52.4M
2
CI icon
Cigna
CI
+$48.2M
3
UTHR icon
United Therapeutics
UTHR
+$38.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$29.4M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$28.9M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$105M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$93.6M
3
THC icon
Tenet Healthcare
THC
+$81.8M
4
BSX icon
Boston Scientific
BSX
+$39.8M
5
CYTK icon
Cytokinetics
CYTK
+$35.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.63%
2 Miscellaneous 2.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMO icon
51
Thermo Fisher Scientific
TMO
$230B
$22.6M 0.53%
46,500
– –
RYTM icon
52
Rhythm Pharmaceuticals
RYTM
$7.38B
$21.7M 0.51%
215,152
-33,360
-13% -$3.1M
ABT icon
53
CALL
Abbott
ABT
$195B
$20.1M 0.47%
+150,000
New +$19.7M
BSX icon
54
CALL
Boston Scientific
BSX
$67.9B
$19.5M 0.46%
+200,000
New +$20.7M
KRYS icon
55
Krystal Biotech
KRYS
$10.4B
$18.1M 0.43%
102,745
+93,545
+1,017% +$14M
FBRX icon
56
Forte Biosciences
FBRX
$18M 0.42%
1,196,955
– –
AVTX icon
57
Avalo Therapeutics
AVTX
$1.05B
$17.1M 0.4%
1,349,300
+382,300
+40% +$3.29M
XENE icon
58
Xenon Pharmaceuticals
XENE
$5.81B
$16.8M 0.4%
419,600
-528,277
-56% -$18.6M
CARL
59
Carlsmed
CARL
$461M
$16.8M 0.39%
+1,252,600
New +$17.1M
KROS icon
60
Keros Therapeutics
KROS
$219M
$16.1M 0.38%
1,018,734
– –
PRLD icon
61
Prelude Therapeutics
PRLD
$437M
$15.7M 0.37%
10,909,256
– –
STTK icon
62
Shattuck Labs
STTK
$707M
$15.1M 0.35%
+6,306,127
New +$7.72M
CRBP icon
63
Corbus Pharmaceuticals
CRBP
$211M
$14.8M 0.35%
1,172,287
– –
URGN icon
64
UroGen Pharma
URGN
$2.13B
$13.7M 0.32%
689,000
+210,600
+44% +$3.78M
VIR icon
65
Vir Biotechnology
VIR
$1.83B
$13.6M 0.32%
2,380,715
– –
FOLD
66
DELISTED
Amicus Therapeutics
FOLD
$13M 0.3%
1,645,400
-640,000
-28% -$4.55M
PFE icon
67
CALL
Pfizer
PFE
$159B
$12.7M 0.3%
+500,000
New +$12.3M
TARS icon
68
Tarsus Pharmaceuticals
TARS
$3.15B
$11.8M 0.28%
197,900
– –
CCCC icon
69
C4 Therapeutics
CCCC
$474M
$11.6M 0.27%
5,235,146
-1,595,154
-23% -$3.83M
AZN icon
70
CALL
AstraZeneca
AZN
$252B
$11.5M 0.27%
75,000
+25,000
+50% +$3.78M
CGEM icon
71
Cullinan Oncology
CGEM
$1.4B
$11.4M 0.27%
1,923,855
– –
VTGN icon
72
VistaGen Therapeutics
VTGN
$11.2M
$10.9M 0.26%
+3,060,000
New +$9.14M
AMLX icon
73
Amylyx Pharmaceuticals
AMLX
$3.87B
$10.2M 0.24%
750,600
+437,400
+140% +$4.12M
ACET icon
74
Adicet Bio
ACET
$84.8M
$9.27M 0.22%
715,446
– –
PMVP icon
75
PMV Pharmaceuticals
PMVP
$65.2M
$8.37M 0.2%
5,975,291
-500,000
-8% -$692K
1 2
3
4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2025 Portfolio in Review

As of Q3 2025, OrbiMed held 127 positions worth $4.26B, up 6.3% from $4B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed withdrew a net $193M in Q3 2025, closing 18 positions and reducing 24 holdings. Its most notable exit was UnitedHealth, an estimated $105M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Danaher worth $52.2M.

  • OrbiMed's largest Q3 2025 buy was Danaher: 263,100 shares worth $52.2M.
  • OrbiMed added most to Ascendis Pharma A/S in Q3 2025, an estimated $29.4M increase.
  • OrbiMed's biggest Q3 2025 reduction was Boston Scientific, cutting an estimated $39.8M.
  • OrbiMed fully exited UnitedHealth in Q3 2025, selling an estimated $105M.
  • OrbiMed's ten largest holdings make up 40% of its $4.26B portfolio in Q3 2025.
  • OrbiMed opened 24 new positions and closed 18 in Q3 2025.
  • OrbiMed's portfolio value rose 6.3% quarter-over-quarter to $4.26B.

Based on OrbiMed's 13F filing for Q3 2025, filed 14 Nov 2025.